Anavex Life Sciences Corp. (AVXL) Trading Down 3.6%
Anavex Life Sciences Corp. (NASDAQ:AVXL)’s share price was down 3.6% during mid-day trading on Tuesday . The company traded as low as $7.10 and last traded at $7.45, with a volume of 1,186,901 shares trading hands. The stock had previously closed at $7.73.
A number of equities analysts recently issued reports on AVXL shares. Maxim Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of Anavex Life Sciences Corp. in a report on Wednesday, June 22nd. Zacks Investment Research downgraded Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, FBR & Co started coverage on Anavex Life Sciences Corp. in a report on Tuesday, March 29th. They issued an “outperform” rating and a $10.00 price target for the company.
The firm’s 50 day moving average is $5.05 and its 200-day moving average is $4.80. The stock’s market capitalization is $244.31 million.
Anavex Life Sciences Corp. (NASDAQ:AVXL) last posted its quarterly earnings data on Wednesday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.10. On average, analysts predict that Anavex Life Sciences Corp. will post ($0.34) EPS for the current fiscal year.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.